

Synthesis of *N*-CycloalkenylazolesAlan R. Katritzky,^{*,‡} Rexiat Maimait,[‡] Yong-Jiang Xu,[‡] and Young Soo Gyoung[§]

Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, Florida 32611-7200, and Department of Chemistry, Kangnung National University, Kangnung, Kangwondo 210-702, Korea

katritzky@chem.ufl.edu

Received May 15, 2002

N-(1-Cycloalkenyl)pyrroles **3a,b**, -pyrazoles **6a,b**, and -imidazoles **9a,b** were synthesized via elimination of benzotriazole or 5-phenyltetrazole from the corresponding 1-[1-(heterocycyl)cycloalkyl]-benzotriazoles **2**, **5**, and **8** or 1-[1-(heterocycyl)cyclohexyl]-5-phenyltetrazole (**12** and **14**). Intermediates **2**, **5**, **8**, **12** and **14** were obtained by cyclizations of dihaloalkanes with *N*-(benzotriazol-1-ylmethyl)heterocycles, 1-imidazol-1-ylmethyl-5-phenyltetrazole (**11**), or 1-pyrazol-1-ylmethyl-5-phenyltetrazole (**13**) in the presence of *n*-BuLi.

Introduction

Molecules containing *N*-(1-cycloalkenyl)heterocycles have potential biological activity; thus, 1-[2-(methylsulfonyl)-1-cyclopentenyl]imidazole (**I**) and 1-[2-(2-thienyl)-1-cyclopentenyl]imidazole (**II**) have been reported as neuronal injury inhibitors¹ (Figure 1); however, few synthetic approaches to compounds of this type have been reported. No literature was found for *N*-(1-cycloalkenyl)-pyrroles **3a,b**. A single paper reported *N*-(1-cyclopent-1-enyl)pyrazole (**6a**) and *N*-(1-cyclohex-1-enyl)pyrazole (**6b**), which were prepared in 73% and 78% yields, respectively, from the corresponding 1,1-bispyrazolylcycloalkanes² (Scheme 1, i). *N*-(1-Cyclohex-1-enyl)imidazole (**9b**) was formed (9% yield) as a byproduct in the preparation of 1,1-bis(imidazol-1-yl)cyclohexane³ (Scheme 1, ii). Compound **II** was obtained (64%) using 1-(2-bromocyclopenten-1-yl)imidazole, (Ph₃P)₄Pd, and 2-thienylboronic acid with NaHCO₃ in DME/H₂O in a German patent¹ (Scheme 1, iii), which also describes the synthesis of **I**.

N-Vinylpyrroles are extensively studied synthetic intermediates;⁴ General routes include (Scheme 2); (i) cyclization of ketoximes and acetylenes in a strong base–DMSO system;⁴ (ii) vinylation of pyrrole in superbase media;⁵ (iii) reactions^{6,7} of potassium pyrrole with epoxides in dry DMF. 1-Vinylimidazoles were also made from the potassium imidazole and corresponding epoxides.^{7,8} A recent paper reported the synthesis of





FIGURE 1.


SCHEME 1

[‡] University of Florida.[§] Kangnung National University.(1) Hoelscher, P.; Rehwinkel, H.; Burton, G.; Moewes, M.; Hillmann, M. Ger. Offen. DE 19627310, 1998; *Chem. Abstr.* **1998**, 128, 114949h.(2) Trofimenko, S. *J. Org. Chem.* **1970**, 35, 3459.(3) Ogata, M.; Matsumoto, H.; Kida, S.; Shimizu, S. *Tetrahedron Lett.* **1979**, 5011.(4) Jones, R. A. *The Chemistry of Heterocyclic Compounds: PYRROLES Part II*; Taylor, E. C., Ed; John Wiley & Sons: New York, 1990; p 143.(5) Trofimov, B. A.; Tarasova, O. A.; Mikhaleva, A. I.; Kalinina, N. A.; Sinegovskaya, L. M.; Henkelmann, J. *Synthesis* **2000**, 1585.(6) Irwin, W. J.; Wheeler, D. L. *Tetrahedron* **1972**, 28, 1113.(7) Cooper, G.; Irwin, W. J.; Weeler, D. L. *Tetrahedron Lett.* **1971**, 4321.

N-vinyl derivatives of nucleobases via direct vinyl exchange of the acetyl group of vinyl acetate with pyrimidine and purine bases using TMSOTf as acid catalyst⁹ (Scheme 2, iv). Palladium–phosphine complexes catalyzed vinylation of various azoles with vinyl bromides to

(8) Cooper, G.; Irwin, W. J. *J. Chem. Soc., Perkin Trans. 1* **1976**, 545.(9) Dalpozzo, R.; De Nino, A.; Maiuolo, L.; Procopio, A.; Romeo, R.; Sindona, G. *Synthesis* **2002**, 172.

SCHEME 2




give *N*-vinylazoles in 30–99% yields (Scheme 2, v).¹⁰ These routes, however, are not directly applicable for the synthesis of *N*-(1-cycloalkenyl)pyrroles or -imidazoles. We now report a new approach to *N*-(1-cycloalkenyl)heteroaromatics using benzotriazole methodology.

Results and Discussion


Synthesis of Cyclic Compounds 2, 5, 8, 12 and 14. *N*-(Benzotriazol-1-ylmethyl)heterocycles were previously synthesized in our group.¹¹ 1-(Imidazol-1-yl)methyl-5-phenyltetrazole (**11**) was synthesized by the reaction of imidazole with 1-chloromethyl-5-phenyltetrazole in the presence of sodium hydroxide in 77% yield, and compound **13** was similarly made from pyrazole and 1-chloromethyl-5-phenyltetrazole in 64% yield. Precursor molecule **1**, **4**, **7**, **11**, or **13** was treated with 2.3 equiv of *n*-BuLi in THF at –78 °C for 1 h followed by the addition of 1,4-dibromobutane or 1,5-dibromopentane to yield the desired 5- or 6-membered cyclic ring systems in moderate to good yields (Schemes 3 and 4). The structures of products **2**, **5**, **8**, **12**, and **14** are clearly characterized by ¹H and ¹³C NMR and microanalysis. The ¹H NMR spectra of the cyclization products showed the absence of any singlet peak around 6.5 ppm that was ascribed to BtCH_2N in the precursor molecules. The expected four separate groups of peaks (for a 6-membered ring) or three groups of peaks (for a 5-membered ring) appear in the aliphatic region.

Synthesis of *N*-(1-Cycloalkenyl)pyrroles, -pyrazoles, and -imidazoles. Two methods have been used in the present work for the removal of benzotriazole to form the *N*-(1-cycloalkenyl)heterocycles: (i) Lewis acid promoted removal of the benzotriazolyl group (method A);¹² (ii) base/DMSO effected removal of the benzotriazole or tetrazole group based on their low pK_a value (method

SCHEME 3^a

^a Key: (a): yields obtained using method A; (b) yields obtained using method B.

SCHEME 4



B). Using the first approach, **6a** and **b** were obtained in 73% and 85% yields by heating of compounds **5a** and **5b**, respectively, with ZnBr_2 in toluene at 80 °C for 30 min (Scheme 3, ii). However, compounds **3a** and **3b** were obtained in only 23% and 20% yields using the same reaction system starting from compounds **2a** and **2b** (Scheme 3, i). Moreover, no desired *N*-(1-cycloalkenyl)-imidazoles were detected in ZnBr_2 /toluene, ZnBr_2 /THF, or ZnBr_2 / CH_2Cl_2 reaction systems after exploring various reaction conditions (varying time and temperature) starting from compound **8** or from **12** in which the tetrazole group was anticipated to be removed more easily than benzotriazole.

Fortunately, the desired compounds **9a,b** were obtained in good yields by the reaction of **8a** (Scheme 3, iii) and **12** (Scheme 4) with KOH/DMSO mixture at 130 °C for 3 h. The expected pyrrole products **3a,b** were

(10) Lebedev, A. Y.; Izmer, V. V.; Kazyul'kin, D. N.; Beletskaya, I. P.; Voskoboinikov, A. Z. *Org. Lett.* **2002**, *4*, 623.

(11) Katritzky, A. R.; Drewniak-Deyrup, M.; Lan, X.; Brunner, F. *J. Heterocycl. Chem.* **1989**, *26*, 829.

(12) Katritzky, A. R.; Lan, X.; Yang, J. Z.; Denisko, O. V. *Chem. Rev.* **1998**, *98*, 409.

obtained in 94% and 77% yields, respectively, as shown in Scheme 3, i, in this KOH/DMSO mixture. The pyrazole products **6a,b** were also formed under this reaction mixture, but the yields were lower than that obtained in the ZnBr₂/toluene system (Scheme 3, ii). However, **6b** was obtained in 89% yield from **14** in KOH/DMSO mixture (Scheme 4). The reasons for these variations in yields are unknown.

The structures of products were fully supported by their ¹H and ¹³C NMR and microanalysis data. In the proton NMR spectrum of **3a**, a multiplet at 5.48–5.50 ppm was ascribed to the vinylic proton in the 5-membered ring. For **6a** and **9a**, a multiplet at 5.85–5.89 ppm and 5.65–5.68 ppm also confirmed the formation of the *N*-(1-cyclopentenyl)heterocycles. Similarly, a multiplet at 5.71–5.74 ppm in the ¹H NMR of **3b** was due to the vinylic proton in the 6-membered ring. For **6b** and **9b**, a multiplet at 6.10–6.13 ppm and 5.82–5.85 ppm also characterized the structures of *N*-(1-cyclohexenyl)heterocycles.

In summary, 1-[1-(heterocycyl)cycloalkyl]benzotriazoles and 1-[1-(heterocycyl)cyclohexyl]-5-phenyltetrazoles were easily obtained via cyclization of the corresponding starting materials in good yields. The benzotriazolyl or 5-phenyltetrazolyl groups in these compounds can be eliminated to give *N*-(1-cycloalkenyl)azoles, a compound class previously rarely reported.

Experimental Section

General Comments. Tetrahydrofuran was distilled under nitrogen from sodium-benzophenone immediately before use. All reactions with moisture-sensitive compounds were carried out under a dry argon atmosphere.

General Procedure for the Synthesis of Compounds 2, 5, 8, 12, and 14. The corresponding starting material (10.0 mmol) was dissolved in THF (180 mL) at –78 °C, and *n*-BuLi (23.0 mmol, 14.4 mL, 1.6 M in hexane) was added dropwise. The resulting solution was stirred for 45–60 min. An appropriate dibromoalkane (1.2 equiv, 12.0 mmol) was then added dropwise. The mixture was stirred overnight and allowed to come to 20 °C. The reaction was quenched with 20 mL of water, and the layers were separated. The aqueous layer was extracted with diethyl ether (3 × 20 mL). The combined organic layer was dried over MgSO₄ and concentrated to give a brown oil. The product was purified by column chromatography on silica gel.

1-[1-(1*H*-Pyrrol-1-yl)cyclopentyl]-1*H*-1,2,3-benzotriazole (2a**):** white prisms (78%) (from ethyl acetate/hexanes); mp 120–123 °C; ¹H NMR δ 1.93–1.98 (m, 4H), 2.73–2.82 (m, 2H), 3.11–3.20 (m, 2H), 6.20 (t, *J* = 2.1 Hz, 2H), 6.87 (t, *J* = 2.1 Hz, 2H), 6.90 (d, *J* = 5.4 Hz, 1H), 7.26–7.33 (m, 2H), 8.00–8.04 (m, 1H); ¹³C NMR δ 22.2, 38.6, 85.3, 109.6, 110.8, 119.0, 119.9, 124.0, 127.5, 131.7, 146.8. Anal. Calcd for C₁₅H₁₆N₄: C, 71.40; H, 6.39; N, 22.20. Found: C, 71.12; H, 6.82; N, 22.23.

1-[1-(1*H*-Pyrrol-1-yl)cyclohexyl]-1*H*-1,2,3-benzotriazole (2b**):** white crystals (68%) (from ethyl acetate/hexanes); mp 120–122 °C; ¹H NMR δ 1.56–1.74 (m, 4H), 1.78–1.90 (m, 2H), 2.60–2.75 (m, 2H), 2.98–3.06 (m, 2H), 6.28 (br s, 2H), 6.32 (d, *J* = 8.1 Hz, 1H), 6.95 (br s, 2H), 7.18–7.29 (m, 2H), 8.00 (d, *J* = 7.8 Hz, 1H); ¹³C NMR δ 22.4, 24.6, 37.4, 78.5, 109.8, 111.0, 118.8, 119.7, 123.8, 127.5, 131.6, 146.2. Anal. Calcd for C₁₆H₁₈N₄: C, 72.15; H, 6.81; N, 21.04. Found: C, 71.77; H, 6.81; N, 20.77.

1-[1-(1*H*-Pyrazol-1-yl)cyclopentyl]-1*H*-1,2,3-benzotriazole (5a**):** white prisms (52%) (from ethyl acetate/hexanes); mp 119–121 °C; ¹H NMR δ 1.92–1.97 (m, 4H), 3.12–3.28 (m, 4H), 6.27 (t, *J* = 2.1 Hz, 1H), 7.30–7.38 (m, 2H), 7.40–7.48 (m, 2H), 7.52–7.58 (m, 1H), 7.98–8.03 (m, 1H); ¹³C NMR δ 22.2, 37.8, 86.9, 107.6, 111.6, 119.9, 124.1, 127.5, 127.7, 131.8,

139.1, 146.8. Anal. Calcd for C₁₄H₁₅N₅: C, 66.38; H, 5.97; N, 27.65. Found: C, 66.32; H, 6.10; N, 27.66.

1-[1-(1*H*-Pyrazol-1-yl)cyclohexyl]-1*H*-1,2,3-benzotriazole (5b**):** white prisms (53%) (from ethyl acetate/hexanes); mp 149–151 °C; ¹H NMR δ 1.55–1.82 (m, 6H), 2.97–3.11 (m, 4H), 6.33 (t, *J* = 1.8 Hz, 1H), 7.07–7.11 (m, 1H), 7.26–7.31 (m, 2H), 7.51 (d, *J* = 2.4 Hz, 1H), 7.63 (br s, 1H), 7.98–8.03 (m, 1H); ¹³C NMR δ 22.2, 24.6, 36.2, 80.3, 107.5, 111.6, 119.9, 123.9, 127.4, 127.5, 131.6, 139.3, 146.5. Anal. Calcd for C₁₅H₁₇N₅: C, 67.39; H, 6.41; N, 26.20. Found: C, 67.43; H, 6.30; N, 26.43.

1-[1-(1*H*-Imidazol-1-yl)cyclopentyl]-1*H*-1,2,3-benzotriazole (8a**):** white prisms (52%) (from chloroform); mp 144–148 °C; ¹H NMR δ 1.94–2.04 (m, 4H), 2.78–2.90 (m, 2H), 3.19–3.28 (m, 2H), 7.00 (s, 1H), 7.04–7.14 (m, 2H), 7.32–7.40 (m, 2H), 7.81 (s, 1H), 8.02–8.10 (m, 1H); ¹³C NMR δ 22.0, 38.4, 83.9, 110.3, 117.4, 120.4, 124.4, 128.1, 130.5, 131.3, 135.1, 147.0. Anal. Calcd for C₁₄H₁₅N₅: C, 66.38; H, 5.97; N, 27.65. Found: C, 66.34; H, 6.35; N, 27.50.

1-[1-(1*H*-Imidazol-1-yl)cyclohexyl]-1*H*-1,2,3-benzotriazole (8b**):** white prisms (40%) (from chloroform); mp 165–167 °C; ¹H NMR δ 1.60–1.90 (m, 6H), 2.62–2.74 (m, 2H), 3.12–3.24 (m, 2H), 6.76–6.84 (m, 1H), 7.00 (s, 1H), 7.10 (s, 1H), 7.29–7.36 (m, 2H), 7.86 (s, 1H), 8.02–8.10 (m, 1H); ¹³C NMR δ 22.2, 24.4, 37.0, 77.6, 110.5, 116.8, 120.4, 124.3, 128.0, 130.4, 131.2, 134.9, 146.6. Anal. Calcd for C₁₅H₁₇N₅: C, 67.39; H, 6.41; N, 26.20. Found: C, 67.67; H, 6.59; N, 26.52.

1-[1-(1*H*-Imidazol-1-yl)cyclohexyl]-5-phenyl-1*H*-1,2,3,4-tetrazole (12**):** white needles (56%) (from chloroform); mp 105–106 °C; ¹H NMR δ 1.40–1.90 (m, 6H), 2.62–2.76 (m, 2H), 3.20–3.54 (m, 2H), 7.04 (s, 1H), 7.19 (s, 1H), 7.44–7.54 (m, 3H), 7.88 (s, 1H), 8.08–8.18 (m, 2H); ¹³C NMR δ 21.9, 24.1, 35.6, 78.1, 116.0, 126.9, 127.0, 128.9, 130.0, 130.6, 134.4, 165.1. Anal. Calcd for C₁₆H₁₈N₆: C, 65.29; H, 6.16; N, 28.55. Found: C, 65.14; H, 6.38; N, 28.43.

1-[1-(1*H*-Pyrazol-1-yl)cyclohexyl]-5-phenyl-1*H*-1,2,3,4-tetrazole (14**):** white prisms (54%) (ethyl acetate/hexanes); mp 111–113 °C; ¹H NMR δ 1.50–1.80 (m, 6H), 2.90–3.20 (m, 4H), 6.31 (br s, 1H), 7.40–7.48 (m, 3H), 7.56 (br s, 1H), 7.74 (d, *J* = 2.4 Hz, 1H), 8.10–8.18 (m, 2H); ¹³C NMR δ 22.0, 24.3, 35.1, 81.3, 106.9, 127.0, 127.2, 127.3, 128.8, 130.3, 140.2, 164.7. Anal. Calcd for C₁₆H₁₈N₆: C, 65.29; H, 6.16; N, 28.55. Found: C, 65.67; H, 6.03; N, 28.71.

Typical Procedure for the Synthesis of *N*-Cycloalkenylazoles. Method A. Compound **2a** (0.25 g, 1 mmol) and ZnBr₂ (0.45 g, 2 mmol) were placed in a dry flask under argon, 5 mL of toluene was added, and the mixture was heated at 80 °C for 45 min. The reaction mixture was then cooled to room temperature, extracted with ethyl ether, dried (MgSO₄), and concentrated to give a white solid that was purified by column chromatography with hexane as eluent to give 30 mg of white powder.

Method B. Compound **2a** (0.10 g, 0.4 mmol) was dissolved in 5 mL of dry DMSO, and KOH powder (0.10 g, 1.6 mmol, 86%) was added. The resulting mixture was heated at 110 °C for 3 h under nitrogen atmosphere with stirring. The reaction mixture was cooled to room temperature and extracted with CH₂Cl₂, the organic layer was washed with water (5 × 5 mL) and dried (Na₂SO₄). The solvent was evaporated under reduced pressure in an ice–water bath. The product was purified by column chromatography on silica gel using 5% ethyl ether in pentane.

***N*-(1-Cyclopenten-1-yl)-1*H*-pyrrole (**3a**):** white solid (from pentane); mp 32–34 °C; ¹H NMR δ 1.99–2.10 (m, 2H), 2.46–2.51 (m, 2H), 2.73–2.79 (m, 2H), 5.48–5.50 (m, 1H), 6.21 (t, *J* = 2.1 Hz, 2H), 6.91 (t, *J* = 2.1 Hz, 2H); ¹³C NMR δ 22.0, 30.5, 31.8, 109.2, 109.3, 118.7, 140.1. Anal. Calcd for C₉H₁₁N: C, 81.16; H, 8.32; N, 10.52. Found: C, 80.98; H, 8.63; N, 10.39.

***N*-(1-Cyclohexen-1-yl)-1*H*-pyrrole (**3b**):** colorless oil; ¹H NMR δ 1.61–1.69 (m, 2H), 1.77–1.85 (m, 2H), 2.14–2.21 (m, 2H), 2.42–2.47 (m, 2H), 5.71–5.74 (m, 1H), 6.18–6.20 (m, 2H), 6.88–6.90 (m, 2H); ¹³C NMR δ 22.0, 22.6, 24.2, 27.1, 108.6,

112.8, 117.9, 136.2; HRMS calcd for $C_{13}H_{13}N$ (M) 147.1048, found 147.1087.

***N*-(1-Cyclopenten-1-yl)-1*H*-pyrazole (6a):**² colorless oil; 1H NMR δ 2.04–2.14 (m, 2H), 2.50–2.58 (m, 2H), 2.83–2.91 (m, 2H), 5.85–5.89 (m, 1H), 6.32–6.33 (m, 1H), 7.59 (br d, J = 2.7 Hz, 1H), 7.60 (d, J = 1.8 Hz, 1H); ^{13}C NMR δ 22.1, 30.7, 31.4, 106.3, 112.3, 127.2, 140.3, 140.4.

***N*-(1-Cyclohexen-1-yl)-1*H*-pyrazole (6b):**² colorless oil; 1H NMR δ 1.63–1.71 (m, 2H), 1.80–1.88 (m, 2H), 2.19–2.26 (m, 2H), 2.55–2.61 (m, 2H), 6.10–6.13 (m, 1H), 6.30–6.31 (m, 1H), 7.58 (br d, J = 1.8 Hz, 1H), 7.61 (dd, J = 2.4, 0.6 Hz, 1H); ^{13}C NMR δ 21.9, 22.4, 24.0, 26.0, 105.8, 113.9, 125.8, 136.5, 139.6.

***N*-(1-Cyclopenten-1-yl)-1*H*-imidazole (9a):** off-white prisms (ethyl acetate/hexanes); mp 40–42 °C; 1H NMR δ 2.04–2.14 (m, 2H), 2.48–2.55 (m, 2H), 2.74–2.81 (m, 2H), 5.65–5.68 (m, 1H), 7.08 (br s, 1H), 7.14–7.16 (m, 1H), 7.67 (br s, 1H); ^{13}C NMR δ 21.8, 30.4, 31.7, 113.3, 116.9, 129.7, 135.1, 136.9; HRMS calcd for $C_8H_{10}N_2$ (M) 134.0844, found 134.0856.

***N*-(1-Cyclohexen-1-yl)-1*H*-imidazole (9b):**³ brown oil; 1H NMR δ 1.65–1.71 (m, 2H), 1.78–1.86 (m, 2H), 2.18–2.22 (m, 2H), 2.40–2.44 (m, 2H), 5.82–5.85 (m, 1H), 7.08 (s, 1H), 7.09 (s, 1H), 7.67 (s, 1H); ^{13}C NMR δ 21.4, 22.1, 23.8, 27.1, 116.2, 116.4, 129.0, 133.5, 134.2.

General Procedure for the Synthesis of Compounds 11 and 13.¹¹ Imidazole or pyrazole (20 mmol) and NaOH

powder (1.6 g, 40 mmol) were dissolved in DMSO (20 mL, dried over molecular sieves) and heated at 60 °C for 30 min. Then, 1-chloromethyl-5-phenyltetrazole (3.8 g, 20 mmol) was added in one portion and the mixture heated at 60 °C for 1 h. The reaction mixture was cooled to room temperature and poured over 100 g of ice in a beaker with rapid stirring. After 10 min, the precipitate was filtered off and washed with cold water (100 mL). The product was purified via recrystallization.

1-(1*H*-Imidazol-1-ylmethyl)-5-phenyl-1*H*-1,2,3,4-tetrazole (11): brown prisms (ethyl acetate/hexanes); mp 123–126 °C; 1H NMR δ 6.65 (s, 2H), 7.11 (s, 1H), 7.24 (s, 1H), 7.45–7.54 (m, 3H), 7.87 (s, 1H), 8.12–8.18 (m, 2H); ^{13}C NMR δ 60.3, 118.9, 126.4, 127.0, 128.9, 130.9, 131.0, 137.4, 166.2. Anal. Calcd for $C_{11}H_{10}N_6$: C, 58.40; H, 4.46; N, 37.15. Found: C, 58.69; H, 4.66; N, 37.03.

1-(1*H*-Pyrazol-1-ylmethyl)-5-phenyl-1*H*-1,2,3,4-tetrazole (13): white needles (ethyl acetate/hexanes); mp 115–116 °C; 1H NMR δ 6.37 (t, J = 2.1 Hz, 1H), 6.82 (s, 2H), 7.46–7.48 (m, 3H), 7.62 (d, J = 1.5 Hz, 1H), 7.80 (d, J = 2.4 Hz, 1H), 8.15–8.18 (m, 2H); ^{13}C NMR δ 64.9, 108.0, 126.6, 126.9, 128.8, 130.3, 130.6, 141.8, 165.8. Anal. Calcd for $C_{11}H_{10}N_6$: C, 58.40; H, 4.46; N, 37.15. Found: C, 58.60; H, 4.40; N, 37.02.

JO020336M